ორშაბათი, აპრილი 13, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Botanical

Fireweed

Chamaenerion angustifolium

Also known as: Ivan Chai, Fireweed herb, Chamaenerion angustifolium, Epilobium angustifolium, Willowherb

LOW RISK 1.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 1.5/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Fireweed (Ivan Chai, Chamaenerion angustifolium) is a traditional Russian/Northern European herbal tea ingredient used for anti-inflammatory, prostate health, and adaptogenic effects. It contains tannins, quercetin, and rutin. Safety data is limited to traditional use. Generally well tolerated. High tannin content may reduce iron absorption when consumed with meals; separate from iron supplements. No significant drug interactions documented.

Classification

Biological and Chemical Classification

Scientific Name
Chamaenerion angustifolium
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 50/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Botanical
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Botanical
Ingredient Fireweed
Scientific name Chamaenerion angustifolium
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Botanical
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Fireweed indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Fireweed
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Chamaenerion angustifolium
50 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 10/10
Evidence transparency 10/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 06 აპრ 2026, 12:10

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Evaluation of the Anticancer Activity of Medicinal Plants Predominantly Accumulating Ellagic Acid Compounds. ↗
    PMID 41300496 ↗
    Journal Antioxidants (Basel)
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/41300496/
    Armonaviu010dius D et al.. Evaluation of the Anticancer Activity of Medicinal Plants Predominantly Accumulating Ellagic Acid Compounds.. Antioxidants (Basel). 2025. PMID:41300496.
  2. Observational / other LOW evidence YELLOW
    Reduced function in Chamaenerion angustifolium after sublethal glyphosate exposure. ↗
    PMID 40851018 ↗
    Journal Sci Rep
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/40851018/
    Wood LJ et al.. Reduced function in Chamaenerion angustifolium after sublethal glyphosate exposure.. Sci Rep. 2025. PMID:40851018.
  3. Observational / other LOW evidence YELLOW
    Epilobieae genomes and the evolution of Myrtales. ↗
    PMID 40696290 ↗
    Journal BMC Plant Biol
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/40696290/
    Wang D et al.. Epilobieae genomes and the evolution of Myrtales.. BMC Plant Biol. 2025. PMID:40696290.
  4. Observational / other LOW evidence YELLOW
    Trace Element and Mineral Content in Medicinal Plants Collected in the Altai Mountains Foothills. ↗
    PMID 40257550 ↗
    Journal Biol Trace Elem Res
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/40257550/
    Tinkov AA et al.. Trace Element and Mineral Content in Medicinal Plants Collected in the Altai Mountains Foothills.. Biol Trace Elem Res. 2025. PMID:40257550.
  5. Observational / other LOW evidence YELLOW
    Phytochemical Insights and Therapeutic Potential of Chamaenerion angustifolium and Chamaenerion latifolium. ↗
    PMID 40076409 ↗
    Journal Molecules
    Year 2025
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/40076409/
    Kozhantayeva A et al.. Phytochemical Insights and Therapeutic Potential of Chamaenerion angustifolium and Chamaenerion latifolium.. Molecules. 2025. PMID:40076409.
  6. Observational / other LOW evidence YELLOW
    Extraction of Bioactive Compounds and Influence of Storage Conditions of Raw Material Chamaenerion angustifolium (L.) Holub Using Different Strategies. ↗
    PMID 39683690 ↗
    Journal Molecules
    Year 2024
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/39683690/
    Armonaviu010dius D et al.. Extraction of Bioactive Compounds and Influence of Storage Conditions of Raw Material Chamaenerion angustifolium (L.) Holub Using Different Strategies.. Molecules. 2024. PMID:39683690.
  7. Observational / other LOW evidence YELLOW
    The genome sequence of rosebay willowherb Chamaenerion angustifolium (L.) Scop., 1771 (syn. Epilobium angustifolium L., 1753) (Onagraceae). ↗
    PMID 38903872 ↗
    Journal Wellcome Open Res
    Year 2024
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/38903872/
    Christenhusz MJM et al.. The genome sequence of rosebay willowherb Chamaenerion angustifolium (L.) Scop., 1771 (syn. Epilobium angustifolium L., 1753) (Onagraceae).. Wellcome Open Res. 2024. PMID:38903872.
  8. Observational / other LOW evidence YELLOW
    Phenological Variations in the Content of Polyphenols and Triterpenoids in Epilobium angustifolium Herb Originating from Ukraine. ↗
    PMID 38202428 ↗
    Journal Plants (Basel)
    Year 2023
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/38202428/
    Ivanauskas L et al.. Phenological Variations in the Content of Polyphenols and Triterpenoids in Epilobium angustifolium Herb Originating from Ukraine.. Plants (Basel). 2023. PMID:38202428.
  9. Observational / other LOW evidence YELLOW
    Deep Eutectic Solvents Based on Carboxylic Acids and Glycerol or Propylene Glycol as Green Media for Extraction of Bioactive Substances from Chamaenerion… ↗
    PMID 37836820 ↗
    Journal Molecules
    Year 2023
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/37836820/
    Koigerova A et al.. Deep Eutectic Solvents Based on Carboxylic Acids and Glycerol or Propylene Glycol as Green Media for Extraction of Bioactive Substances from Chamaenerion angustifolium (L.) Scop.. Molecules. 2023. PMID:37836820.
  10. Observational / other LOW evidence YELLOW
    Mass Spectrometric Fingerprint Mapping Reveals Species-Specific Differences in Plant Polyphenols and Related Bioactivities. ↗
    PMID 37687216 ↗
    Journal Molecules
    Year 2023
    Study type Observational / other
    Evidence strength LOW evidence
    PubMed link https://pubmed.ncbi.nlm.nih.gov/37687216/
    Vanhakylu00e4 S et al.. Mass Spectrometric Fingerprint Mapping Reveals Species-Specific Differences in Plant Polyphenols and Related Bioactivities.. Molecules. 2023. PMID:37687216.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 1.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 1.5 / 10

Final GIRI Score for Fireweed. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 1.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
1.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Fireweed

GIRI Score 1.5 / 10

A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

ბოლო სიახლეები

პოპულარული ამბები

კატეგორიები

ჩვენ შესახებ

info@accreditation.ge
ჩვენს შესახებ / რეკლამა / კონტაქტი

გამოგვყევი სოციალურ ქსელებში

© SheniEkimi.ge